Publikationen, an denen er mitarbeitet Antonio Llombart Cussac (18)

2019

  1. Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

    Clinical Cancer Research

2018

  1. ERþ Breast cancers resistant to prolonged neoadjuvant letrozole exhibit an e2f4 transcriptional program sensitive to cdk4/6 inhibitors

    Clinical Cancer Research, Vol. 24, Núm. 11, pp. 2517-2529

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. Critically short telomeres and toxicity of chemotherapy in early breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

2012

  1. Progress against solid tumors in danger: The metastatic breast cancer example

    Journal of Clinical Oncology

2010

  1. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  2. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

2009

  1. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer

    Journal of Clinical Oncology, Vol. 27, Núm. 11, pp. 1753-1760

2008

  1. Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007

    Clinical and Translational Oncology, Vol. 10, Núm. 9, pp. 552-559

  2. Time-to-progression in breast cancer: A stratification model for clinical trials

    Breast, Vol. 17, Núm. 3, pp. 239-244

2007

  1. Current controversies in the management of early breast cancer

    Clinical and Translational Oncology, Vol. 9, Núm. 6, pp. 375-384

2006

  1. The «El Álamo» project (1990-1997): Two consecutive hospital-based studies of breast cancer outcomes in Spain

    Clinical and Translational Oncology, Vol. 8, Núm. 7, pp. 508-518

2005

  1. Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks

    Breast Cancer Research and Treatment, Vol. 94, Núm. 3, pp. 265-272

2004

  1. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain

    Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206

  2. Estudio epidemiológico del grupo GEICAM sobre el cáncer de mama en España (1990-1993): Proyecto «El Álamo»

    Medicina Clinica, Vol. 122, Núm. 1, pp. 12-17

  3. Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM) [1]

    Journal of Clinical Oncology

2003

  1. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients

    Annals of Oncology, Vol. 14, Núm. 9, pp. 1383-1390

1999

  1. Treatment with a nonanthracycline regimen in advanced breast cancer: Vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 22, Núm. 2, pp. 196-198